<DOC>
	<DOCNO>NCT02252588</DOCNO>
	<brief_summary>Determine effect twice-daily chlorhexidine oral rinse oral lung microbiota biomass subject chronic obstructive pulmonary disease ( COPD ) chronic bronchitis . Our primary outcome compare microbiota biomass ( number bacteria measure 16S rRNA copy number ) induce sputum oral cavity 8 week twice-daily chlorhexidine oral rinse ( n=25 ) compare control ( n=25 ) use qPCR next-generation sequence bacterial 16S rRNA gene compare total bacterial biomass</brief_summary>
	<brief_title>The Effect Chlorhexidine Oral Lung Microbiota Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description>Our hypothesis 8 week chlorhexidine oral rinse decrease microbiota biomass compare baseline placebo . Furthermore , hypothesize chlorhexidine treatment : ) decrease lung oral microbiota diversity ; ii ) alter microbiota taxonomic composition lung oral cavity ; iii ) decrease systemic inflammation measure blood high sensitivity C-reactive protein ( hsCRP ) , fibrinogen leukocyte count ; iv ) demonstrate trend towards improvement respiratory health status measure Breathlessness , Cough , Sputum Scale ( BCSS ) [ 1 , 2 ] St. George 's Respiratory Questionnaire ( SGRQ ) . Subaim 1 : Determine chlorhexidine alters lung oral rinse microbiota diversity taxonomic composition . Our hypothesis chlorhexidine oral rinse decrease diversity ( Shannon inverse Simpson diversity index ) taxonomic composition oral lung microbiota compare placebo determine next-generation sequence bacterial 16S rRNA gene . Subaim 2 : Determine impact chlorhexidine systemic inflammation . Our hypothesis decrease lung microbiota biomass associate decrease systemic inflammation measure blood hsCRP , fibrinogen , leukocyte count . Subaim 3 : Determine respiratory symptom associate lung microbiota biomass . Our hypothesis chlorhexidine demonstrate improve respiratory health status measure BCSS SGRQ .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chlorhexidine</mesh_term>
	<mesh_term>Chlorhexidine gluconate</mesh_term>
	<criteria>Willingness undergo sputum induction Capability provide write informed consent Age ≥ 40 year ≤ 85 year FEV1/FVC ratio ( post bronchodilator ) ≤70 % FEV1 ( post bronchodilator ) ≤ 65 % Presence high likelihood chronic cough sputum production define one following : Presence chronic cough sputum define response first two question SGRQ . Subjects respond positively question 1 ( cough ) question 2 ( sputum ) SGRQ either `` several day per week '' `` almost every day '' eligible . COPD exacerbation within previous 12 month define take antibiotic and/or prednisone respiratory symptom , hospitalization emergency department visit respiratory illness . Current former smoker lifetime cigarette consumption &gt; 10 packyears Negative serum pregnancy test baseline visit patient premenopausal female ( menopause define absence menstrual cycle last 12 month ) Must fluent speak English language Have minimum four teeth Not fully recover least 30 day COPD exacerbation . Treated antibiotic last 2 month . The presence denture ( full plate ) . Active oral infection treat health care professional . Current use chlorhexidine overthecounter mouth wash last 2 month . Known allergy sensitivity chlorhexidine Unstable cardiac disease Clinical diagnosis asthma , bronchiectasis , cystic fibrosis , severe alpha1 antitrypsin deficiency Active lung cancer history lung cancer le 2 year since lung resection treatment . If history lung cancer , must evidence recurrence 2 year precede baseline visit .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>COPD</keyword>
	<keyword>Bacteria</keyword>
</DOC>